240 related articles for article (PubMed ID: 21320541)
1. A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritis.
Wang D; Suhrbier A; Penn-Nicholson A; Woraratanadharm J; Gardner J; Luo M; Le TT; Anraku I; Sakalian M; Einfeld D; Dong JY
Vaccine; 2011 Mar; 29(15):2803-9. PubMed ID: 21320541
[TBL] [Abstract][Full Text] [Related]
2. Chikungunya virus arthritis in adult wild-type mice.
Gardner J; Anraku I; Le TT; Larcher T; Major L; Roques P; Schroder WA; Higgs S; Suhrbier A
J Virol; 2010 Aug; 84(16):8021-32. PubMed ID: 20519386
[TBL] [Abstract][Full Text] [Related]
3. Effective chikungunya virus-like particle vaccine produced in insect cells.
Metz SW; Gardner J; Geertsema C; Le TT; Goh L; Vlak JM; Suhrbier A; Pijlman GP
PLoS Negl Trop Dis; 2013; 7(3):e2124. PubMed ID: 23516657
[TBL] [Abstract][Full Text] [Related]
4. Adenoviral-Vectored Mayaro and Chikungunya Virus Vaccine Candidates Afford Partial Cross-Protection From Lethal Challenge in A129 Mouse Model.
Campos RK; Preciado-Llanes L; Azar SR; Kim YC; Brandon O; López-Camacho C; Reyes-Sandoval A; Rossi SL
Front Immunol; 2020; 11():591885. PubMed ID: 33224148
[TBL] [Abstract][Full Text] [Related]
5. A chimeric vesiculo/alphavirus is an effective alphavirus vaccine.
Chattopadhyay A; Wang E; Seymour R; Weaver SC; Rose JK
J Virol; 2013 Jan; 87(1):395-402. PubMed ID: 23077320
[TBL] [Abstract][Full Text] [Related]
6. Non-replicating adenovirus based Mayaro virus vaccine elicits protective immune responses and cross protects against other alphaviruses.
Powers JM; Haese NN; Denton M; Ando T; Kreklywich C; Bonin K; Streblow CE; Kreklywich N; Smith P; Broeckel R; DeFilippis V; Morrison TE; Heise MT; Streblow DN
PLoS Negl Trop Dis; 2021 Apr; 15(4):e0009308. PubMed ID: 33793555
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus.
Muthumani K; Lankaraman KM; Laddy DJ; Sundaram SG; Chung CW; Sako E; Wu L; Khan A; Sardesai N; Kim JJ; Vijayachari P; Weiner DB
Vaccine; 2008 Sep; 26(40):5128-34. PubMed ID: 18471943
[TBL] [Abstract][Full Text] [Related]
8. Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice.
Hallengärd D; Kakoulidou M; Lulla A; Kümmerer BM; Johansson DX; Mutso M; Lulla V; Fazakerley JK; Roques P; Le Grand R; Merits A; Liljeström P
J Virol; 2014 Mar; 88(5):2858-66. PubMed ID: 24371047
[TBL] [Abstract][Full Text] [Related]
9. Probing the attenuation and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised interferon (IFN) signaling.
Partidos CD; Weger J; Brewoo J; Seymour R; Borland EM; Ledermann JP; Powers AM; Weaver SC; Stinchcomb DT; Osorio JE
Vaccine; 2011 Apr; 29(16):3067-73. PubMed ID: 21300099
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus.
Kumar M; Sudeep AB; Arankalle VA
Vaccine; 2012 Sep; 30(43):6142-9. PubMed ID: 22884660
[TBL] [Abstract][Full Text] [Related]
11. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection.
Akahata W; Yang ZY; Andersen H; Sun S; Holdaway HA; Kong WP; Lewis MG; Higgs S; Rossmann MG; Rao S; Nabel GJ
Nat Med; 2010 Mar; 16(3):334-8. PubMed ID: 20111039
[TBL] [Abstract][Full Text] [Related]
12. Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose.
Roy CJ; Adams AP; Wang E; Plante K; Gorchakov R; Seymour RL; Vinet-Oliphant H; Weaver SC
J Infect Dis; 2014 Jun; 209(12):1891-9. PubMed ID: 24403555
[TBL] [Abstract][Full Text] [Related]
13. Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits.
Metz SW; Martina BE; van den Doel P; Geertsema C; Osterhaus AD; Vlak JM; Pijlman GP
Vaccine; 2013 Dec; 31(51):6092-6. PubMed ID: 24099875
[TBL] [Abstract][Full Text] [Related]
14. Chimeric alphavirus vaccine candidates for chikungunya.
Wang E; Volkova E; Adams AP; Forrester N; Xiao SY; Frolov I; Weaver SC
Vaccine; 2008 Sep; 26(39):5030-9. PubMed ID: 18692107
[TBL] [Abstract][Full Text] [Related]
15. Liposomal Delivery of the RNA Genome of a Live-Attenuated Chikungunya Virus Vaccine Candidate Provides Local, but Not Systemic Protection After One Dose.
Abeyratne E; Tharmarajah K; Freitas JR; Mostafavi H; Mahalingam S; Zaid A; Zaman M; Taylor A
Front Immunol; 2020; 11():304. PubMed ID: 32194557
[TBL] [Abstract][Full Text] [Related]
16. An adjuvanted adenovirus 5-based vaccine elicits neutralizing antibodies and protects mice against chikungunya virus-induced footpad swelling.
Dora EG; Rossi SL; Weaver SC; Tucker SN; Mateo R
Vaccine; 2019 May; 37(24):3146-3150. PubMed ID: 31047675
[TBL] [Abstract][Full Text] [Related]
17. Chikungunya Virus Vaccines: Viral Vector-Based Approaches.
Ramsauer K; Tangy F
J Infect Dis; 2016 Dec; 214(suppl 5):S500-S505. PubMed ID: 27920181
[TBL] [Abstract][Full Text] [Related]
18. Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine.
Partidos CD; Paykel J; Weger J; Borland EM; Powers AM; Seymour R; Weaver SC; Stinchcomb DT; Osorio JE
Vaccine; 2012 Jun; 30(31):4638-43. PubMed ID: 22583812
[TBL] [Abstract][Full Text] [Related]
19. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus.
Brandler S; Ruffié C; Combredet C; Brault JB; Najburg V; Prevost MC; Habel A; Tauber E; Desprès P; Tangy F
Vaccine; 2013 Aug; 31(36):3718-25. PubMed ID: 23742993
[TBL] [Abstract][Full Text] [Related]
20. Chimeric Chikungunya viruses are nonpathogenic in highly sensitive mouse models but efficiently induce a protective immune response.
Wang E; Kim DY; Weaver SC; Frolov I
J Virol; 2011 Sep; 85(17):9249-52. PubMed ID: 21697494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
